Giant Lymph Node Hyperplasia
7
1
1
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
14.3%
1 terminated out of 7 trials
75.0%
-11.5% vs benchmark
14%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
International Registry for Patients With Castleman Disease
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Unlock the Cell: Castleman's Disease Flow Cytometry Study
Castleman Disease Collaborative Network Biobank
Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy